SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics to start pilot production trial run in Unit IV on November 25

23 Nov 2017 Evaluate

Lasa Supergenerics will be commencing its pilot production trial runs in Unit IV effective from November 25, 2017. Products & capacity per annum will include Albendazole Intermediate 400 MT, Fenbendazole Intermediate 200MT, 2 4 DCP 600MT, Closantel Intermediate 100MT and additionally few components of backward integration for its recent new launches.

Lasa Supergenerics manufactures and distributes chemicals. The company offers veterinary API products, animal feed ingredients, and reagents for therapeutic uses.

Lasa Supergenerics Share Price

8.77 0.30 (3.54%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×